Toronto, Canada (15 August 2006) - glisodin.org, an international research community dedicated to the Glisodin SOD/gliadin complex, announces the inclusion of a key study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In this study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group as compared to no change in the control and placebo group. SOD is an endogenous antioxidant produced by the body at the cellular level, providing the first line of defense against oxidative stress.

"The effects of an orally effective SOD (Glisodin) on AIDS West African patients in a randomized double-blinded clinical study," was conducted by French and American Researchers with HIV patients in the Ivory Coast. http://www.iasociety.org/abstract/show.asp?abstract_id=2180443.

Acquired immunodeficiency syndrome (AIDS) is associated with oxidative stress that is responsible for the development of pro-inflammatory disorders and organ failures. In addition, usual anti-retroviral therapies induce important oxidative disorders in promoting mitochondrial swelling, and thus contribute to the development of oxidative disorders in HIV/AIDS infected patients.

The cumulative pro-oxidant effects of the infectious process itself and the potential toxicity of the anti-retroviral therapies could be the origin of most of the inflammatory and toxicological disorders observed in these patients. The objectives of the study were to assess the effects of orally effective SOD/gliadin (Glisodin) on AIDS patients.

In the study, thirty-five AIDS patients were blindly divided into three groups: 1. Placebo (n=12); 2. Non-protected SOD (1000 IU/day, n = 12) as a control; and 3. SOD/Gliadin (Glisodin) product (1000 IU /per day, n = 11). The study products were to be taken once daily, orally for 21 days. Prior to the study, it was first documented that the circulating antioxidant status and the endogenous SOD levels of the study population (n=35) was significantly decreased (p < 0.01) compared to non-infected healthy West African donors.

A statistically significant restoration of the circulating antioxidant capacities was observed in AIDS patients (n = 11) taking the SOD/Gliadin (Glisodin) product: SOD1 activity (p<0.01), Gpx activity (p<0.05), total antioxidant status (p<0.001) and significantly reduced b2-microglobulin plasma concentration (p < 0.01) , during the same period no significant effects were observed for the Non-protected SOD and Placebo groups. This demonstrates that only the SOD/Gliadin preparation was able to efficiently support the antioxidant defenses in AIDS patients.

The authors concluded, "The statistically significant antioxidant restoration and decreased b2-microglobulin concentration in Glisodin-supplemented AIDS patients suggests a beneficial effect of the Glisodin product in HIV/AIDS patients. These results suggest that these patients will be prepared for a better compliance and a better efficacy to the anti-retroviral therapy."

www.Glisodin.org provides research links and studies establishing proof of concept in vitro and in vivo, and efficacy in animal and human models. Human studies include protection of mitochondrial DNA, inhibition of isoprostanes, protection against UV radiation and sun allergy, and other therapeutic benefits of Glisodin supplementation.

International contact: Francois Vix [33] 1 53 98 85 00

U.S. Contact: Eric Anderson
480-227-9383
[email protected]

# # #

glisodin.org is a research community dedicated to the understanding and advancement of glisodin SOD/gliadin complex. www.glisodin.org